Caribou Biosciences (CRBU) Non-Current Deferred Tax Liability (2020 - 2025)

Caribou Biosciences (CRBU) has reported Non-Current Deferred Tax Liability for 6 consecutive years, with $4.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Non-Current Deferred Tax Liability fell 47.23% year-over-year to $4.3 million; the TTM figure through Dec 2025 stood at $4.3 million (down 47.23% YoY), while the FY2025 annual figure was $4.3 million, down 47.23% from the prior year.
• Non-Current Deferred Tax Liability rose to $4.3 million in Q4 2025 per CRBU's latest filing, from $548000.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $10.9 million in Q4 2022 and bottomed at $155000.0 in Q2 2021.
• Historically, Non-Current Deferred Tax Liability has averaged $1.8 million across 5 years, with a median of $548000.0 in 2025.
• Annual changes were most pronounced in 2021 — Non-Current Deferred Tax Liability surged 2043.87% — and 2023, when it tumbled 94.88%.
• Caribou Biosciences' Non-Current Deferred Tax Liability stood at $3.3 million in 2021, then soared by 227.54% to $10.9 million in 2022, then sank by 94.88% to $557000.0 in 2023, then soared by 1351.17% to $8.1 million in 2024, then tumbled by 47.23% to $4.3 million in 2025.
• Business Quant data shows CRBU's Non-Current Deferred Tax Liability at $4.3 million in Q4 2025, $548000.0 in Q3 2025, and $548000.0 in Q2 2025.